Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A p53-responsive microRNA network promotes cancer cell quiescence.

La T, Liu GZ, Farrelly M, Cole N, Feng YC, Zhang YY, Sherwin SK, Yari H, Tabatabaee H, Yan XG, Guo ST, Liu T, Thorne RF, Jin L, Zhang XD.

Cancer Res. 2018 Oct 9. pii: canres.1886.2018. doi: 10.1158/0008-5472.CAN-18-1886. [Epub ahead of print]

PMID:
30301840
2.

Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome.

Rao G, Nkepang G, Xu J, Yari H, Houson H, Teng C, Awasthi V.

Front Chem. 2018 Sep 10;6:392. doi: 10.3389/fchem.2018.00392. eCollection 2018.

3.

Induction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24.

Rao G, Houson H, Nkepang G, Yari H, Teng C, Awasthi V.

Am J Physiol Gastrointest Liver Physiol. 2018 Aug 1;315(2):G318-G327. doi: 10.1152/ajpgi.00066.2018. Epub 2018 May 10.

PMID:
29746173
4.

Sensitivity and Specificity of Modified Bragard Test in Patients With Lumbosacral Radiculopathy Using Electrodiagnosis as a Reference Standard.

Homayouni K, Jafari SH, Yari H.

J Chiropr Med. 2018 Mar;17(1):36-43. doi: 10.1016/j.jcm.2017.10.004. Epub 2018 Jan 12.

5.

Stability study on an anti-cancer drug 4-(3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid (CLEFMA) using a stability-indicating HPLC method.

Raghuvanshi D, Nkepang G, Hussain A, Yari H, Awasthi V.

J Pharm Anal. 2017 Feb;7(1):1-9. doi: 10.1016/j.jpha.2016.09.004. Epub 2016 Sep 28.

6.

A comparison of H-reflex in the triceps surae muscle group in patients with S1 radiculopathy.

Emad MR, Momeninejad H, Pourabbas Tahvildari B, Yari H.

Somatosens Mot Res. 2017 Dec;34(4):213-218. doi: 10.1080/08990220.2017.1415878. Epub 2018 Jan 8.

PMID:
29307252
7.

The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue Subscale): Validity and Reliability of the Iranian Version.

Meysami A, Yari H, Haghighat S, Montazeri A.

Oncol Res Treat. 2017;40(12):789-793. doi: 10.1159/000479588. Epub 2017 Nov 29.

PMID:
29183033
8.

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.

Liu F, Jiang CC, Yan XG, Tseng HY, Wang CY, Zhang YY, Yari H, La T, Farrelly M, Guo ST, Thorne RF, Jin L, Wang Q, Zhang XD.

Oncotarget. 2017 May 9;8(41):69477-69492. doi: 10.18632/oncotarget.17704. eCollection 2017 Sep 19.

9.

Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress.

Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, Yan XG, Thorne RF, Scolyer RA, Zhang XD, Jin L.

Cancer Res. 2017 Nov 15;77(22):6226-6239. doi: 10.1158/0008-5472.CAN-17-1965. Epub 2017 Sep 25.

PMID:
28947420
10.

Reactive Oxygen Species Dictate the Apoptotic Response of Melanoma Cells to TH588.

Wang JY, Jin L, Yan XG, Sherwin S, Farrelly M, Zhang YY, Liu F, Wang CY, Guo ST, Yari H, La T, McFarlane J, Lei FX, Tabatabaee H, Chen JZ, Croft A, Jiang CC, Zhang XD.

J Invest Dermatol. 2016 Nov;136(11):2277-2286. doi: 10.1016/j.jid.2016.06.625. Epub 2016 Jul 15.

11.

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.

Wang CY, Guo ST, Wang JY, Yan XG, Farrelly M, Zhang YY, Liu F, Yari H, La T, Lei FX, Jin L, Zhang XD, Jiang CC.

Oncotarget. 2016 Aug 2;7(31):49597-49610. doi: 10.18632/oncotarget.10414.

12.

Benefits and Complications of Removing Ureteral Stent Based on the Elapsed Time After Renal Transplantation Surgery.

Dadkhah F, Yari H, Ali Asgari M, Fallahnezhad MH, Tavoosian A, Ghadian A.

Nephrourol Mon. 2016 Mar 12;8(2):e31108. doi: 10.5812/numonthly.31108. eCollection 2016 Mar.

13.

Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.

Wang CY, Guo ST, Wang JY, Liu F, Zhang YY, Yari H, Yan XG, Jin L, Zhang XD, Jiang CC.

Mol Cancer Ther. 2016 Mar;15(3):448-59. doi: 10.1158/1535-7163.MCT-15-0778. Epub 2016 Feb 1.

14.

In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors.

Yari H, Ganjalikhany MR, Sadegh H.

Comput Biol Chem. 2015 Dec;59 Pt A:185-98. doi: 10.1016/j.compbiolchem.2015.09.013. Epub 2015 Oct 9.

PMID:
26580563
15.

Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.

Suzuki N, Shiota T, Watanabe F, Haga N, Murashi T, Ohara T, Matsuo K, Omori N, Yari H, Dohi K, Inoue M, Iguchi M, Sentou J, Wada T.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):456-60. doi: 10.1016/j.bmcl.2011.10.103. Epub 2011 Nov 6.

PMID:
22101132
16.

Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors.

Suzuki N, Shiota T, Watanabe F, Haga N, Murashi T, Ohara T, Matsuo K, Oomori N, Yari H, Dohi K, Inoue M, Iguchi M, Sentou J, Wada T.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1601-6. doi: 10.1016/j.bmcl.2011.01.119. Epub 2011 Feb 2.

PMID:
21334203
17.

Design and synthesis of an artificial ladder-shaped polyether that interacts with glycophorin A.

Torikai K, Yari H, Mori M, Ujihara S, Matsumori N, Murata M, Oishi T.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6355-9. Epub 2006 Sep 20.

PMID:
16989999
18.

(Z)-Selective cross-dimerization of arylacetylenes with silylacetylenes catalyzed by vinylideneruthenium complexes.

Katayama H, Yari H, Tanaka M, Ozawa F.

Chem Commun (Camb). 2005 Sep 14;(34):4336-8. Epub 2005 Jul 28.

PMID:
16113740

Supplemental Content

Support Center